| Literature DB >> 30444898 |
Arthur H P Mawuntu1, Janno B B Bernadus1, Rama Dhenni2, Ageng Wiyatno2, Riane Anggreani1, Frilasita A Yudhaputri2, Ungke Anton Jaya3, Chairin Nisa Ma'roef2, Aghnianditya K Dewantari2, Araniy Fadhilah2, Jeremy P Ledermann4, Ann M Powers4, Dodi Safari2, Khin Saw Aye Myint2.
Abstract
Central nervous system (CNS) viral infections are important causes of morbidity and mortality worldwide but the systematic survey of patients admitted to hospitals with CNS infections in many countries, including Indonesia, is limited. To obtain more information regarding the causes of CNS infections in Indonesia, this study was performed to detect and identify viral agents associated with CNS infections amongst in-patients at a referral hospital in Manado, North Sulawesi, Indonesia. Adult patients admitted to R.D. Kandou General Hospital with presumed CNS infection were enrolled. Cerebrospinal fluid, serum, and throat swab samples were collected and tested using molecular, serological, and virus isolation assays. A confirmed viral etiology was established in three and a probable/possible in 11 out of 74 patients. The most common was herpes simplex virus 1 (7/74, 9.5%), followed by Epstein-Barr virus (2/74, 2.7%), cytomegalovirus (1/74, 1.4%), enterovirus D68 (1/74, 1.4%), rhinovirus A (1/74, 1.4%), dengue virus (1/64, 1.6%), and Japanese encephalitis virus (1/64, 1.6%). There were 20 fatal cases (27.0%) during hospitalization in which eight were associated with viral causes. We identified herpes simplex virus 1 as the most common cause of CNS infection among adults in North Sulawesi with most of the cases remaining undiagnosed. Our study highlights the challenges in establishing the etiology of viral CNS infections and the importance of using a wide range of molecular and serological detection methods to identify CNS viruses.Entities:
Mesh:
Year: 2018 PMID: 30444898 PMCID: PMC6239303 DOI: 10.1371/journal.pone.0207440
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram for total enrolled cases, collected samples available, and assays performed for different sample types in the study.
Characteristics of adult patients with suspected CNS infection enrolled in this study.
| Parameter | All cases | Diagnosed | Undiagnosed | ||
|---|---|---|---|---|---|
| Age, median (range) | 31 (15⎼72) | 30 (15⎼68) | 31 (15⎼72) | ||
| Sex, male | 49 (66.2) | 7 (50.0) | 42 (70.0) | ||
| High grade fever (axillary temperature ≥39°C) | 54 (73.0) | 9 (64.3) | 45 (75.0) | ||
| Day of illness at admission, median (range) | 7 (1⎼90) | 6 (1⎼30) | 7 (1⎼90) | ||
| Duration of hospital stay, median (range) | 12.5 (2⎼51) | 11 (5⎼38) | 12.5 (2⎼51) | ||
| Survived patients | 12.5 (2⎼51) | 11.5 (7⎼15) | 12.5 (2⎼51) | ||
| Deceased patients | 11.5 (4⎼38) | 10.5 (5⎼38) | 12.5 (4⎼30) | ||
| Headache | 50 (67.6) | 7 (50.0) | 43 (71.7) | ||
| Seizures | 28 (37.8) | 7 (50.0) | 21 (35.0) | ||
| Altered consciousness | 55 (74.3) | 13 (92.9) | 42 (70.0) | ||
| Skin rash | 7 (9.5) | 2 (14.3) | 5 (8.3) | ||
| Myalgia | 11 (14.9) | 3 (21.4) | 8 (13.3) | ||
| Focal neurologic signs | 29 (39.2) | 4 (28.6) | 25 (41.7) | ||
| Glasgow Coma Scale, median (range) | 13 (3⎼15) | 10.5 (3⎼15) | 13.5 (7⎼15) | ||
| Cognitive impairment | 7/67 (10.5) | 3/14 (21.4) | 4/53 (7.6) | ||
| HIV-positive status | 23 (31.1) | 5 (35.7) | 18 (30.0) | ||
| TB-positive history status | 33 (44.6) | 4 (28.6) | 33 (55.0) | ||
| Cryptococcus-positive | 6 (8.1) | 0 (0.0) | 6 (10.0) | ||
| CSF total cell count, cells/μl, median (range) | 5 (0⎼3,750) | 5 (0⎼200) | 5 (0⎼3,750) | ||
| CSF mononuclear cell count, cells/μl, median (range) | 20 (0⎼100) | 10 (0⎼95) | 20 (0⎼100) | ||
| CSF polymorphonuclear cell count, cells/μl, median (range) | 2 (0⎼90) | 2.5 (0⎼80) | 2 (0⎼90) | ||
| CSF protein mg/dl, median (range) | 40 (10⎼1,730) | 120 (20⎼730) | 40 (10⎼1,730) | ||
| CSF glucose mg/dl, median (range) | 62 (5⎼135) | 68 (33⎼135) | 58 (5⎼128) | ||
| CSF/serum glucose ratio <0.4 | 7 (18.0) | 0 (0.0) | 7 (20.6) | ||
| Leukocytosis | 39 (52.7) | 7 (50.0) | 32 (53.3) | ||
| Leukopenia | 3 (4.1) | 0 (0.0) | 3 (5.0) | ||
| Thrombocytosis | 4 (5.4) | 2 (14.3) | 2 (3.3) | ||
| Thrombocytopenia | 5 (6.8) | 1 (7.1) | 4 (6.7) | ||
| Elevated ALT | 17/70 (24.3) | 6/14 (42.9) | 11/56 (19.6) | ||
| Elevated AST | 33/70 (47.1) | 9/14 (64.3) | 24/56 (42.9) | ||
| CT scan, abnormal | 42/61 (68.9) | 5/9 (55.6) | 37/52 (71.2) | ||
| Meningeal enhancement | 22/60 (36.7) | 2/9 (22.2) | 20/51 (39.2) | ||
| Focal brain lesions | 12/60 (20.0) | 1/9 (11.1) | 11/51 (21.6) | ||
| Death (GOS = 1) | 20 (27.0) | 8 (57.1) | 12 (20.0) | ||
| Persistent vegetative state (GOS = 2) | 12 (16.2) | 0 (0.0) | 12 (20.0) | ||
| Severe disability (GOS = 3) | 7 (9.5) | 1 (7.1) | 6 (10.0) | ||
| Moderate disability (GOS = 4) | 15 (20.3) | 4 (28.6) | 11 (18.3) | ||
| Low disability (GOS = 5) | 20 (27.0) | 1 (7.1) | 19 (31.7) | ||
| Neurological sequelae | 20/54 (37.0) | 0/6 (0.0) | 20/48 (41.7) | ||
| Cognitive sequelae | 16/54 (29.6) | 2/6 (33.3) | 14/48 (29.2) | ||
Data are presented as number of patients (%) unless indicated otherwise. HIV, human immunodeficiency virus; TB, Tuberculosis; ALT, alanine transaminase; AST, aspartate transaminase; GOS, Glasgow Outcome Score.
an as in column heading unless otherwise specified in individual rows. Percentage noted in parentheses unless otherwise noted.
bData available from 39 patients (6 diagnosed and 33 undiagnosed).
cP-value < 0.01 when comparing patients with identified etiology to those undiagnosed.
dP-value < 0.05 when comparing patients with identified etiology to those undiagnosed.
Viral diagnostic assays and detection from adult patients with suspected CNS infection.
| Virus diagnostic assays | Number of samples, positive/tested | Number of patients, positive/tested (%) | Number of patients with CNS viral infection diagnosis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CSF | Serum | Throat Swab | Confirmed | Probable | Possible | ||||
| Alphavirus | 0/38 | 0/36 | ND | 0/64 (0) | 0 | 0 | 0 | ||
| Flavivirus | 0/38 | 0/36 | ND | 0/64 (0) | 0 | 0 | 0 | ||
| Filovirus | 0/38 | 0/36 | 0/26 | 0/74 (0) | 0 | 0 | 0 | ||
| Paramyxovirus | 0/38 | 0/36 | 0/26 | 0/74 (0) | 0 | 0 | 0 | ||
| Coronavirus set 1 | 0/38 | 0/36 | 0/26 | 0/74 (0) | 0 | 0 | 0 | ||
| Coronavirus set 2 | 0/38 | 0/36 | 0/26 | 0/74 (0) | 0 | 0 | 0 | ||
| Herpesvirus | |||||||||
| HSV-1 | 1/38 | 1/36 | 5/26 | 7/74 (9.5) | 1 | 0 | 6 | ||
| EBV | 0/38 | 0/36 | 2/26 | 2/74 (2.7) | 0 | 0 | 2 | ||
| CMV | 1/38 | 0/36 | 0/26 | 1/74 (1.4) | 1 | 0 | 0 | ||
| Enterovirus | |||||||||
| EV-D68 | 0/38 | 0/36 | 1/26 | 1/74 (1.4) | 0 | 0 | 1 | ||
| RV-A | 0/38 | 0/36 | 1/26 | 1/74 (1.4) | 0 | 0 | 1 | ||
| Anti-DENV IgM | 1/38 | 1/36 | ND | 1/64 (1.6) | 1 | 0 | 0 | ||
| Anti- JEV IgM | 0/38 | 1/36 | ND | 1/64 (1.6) | 0 | 1 | 0 | ||
| 0/38 | ND | ND | 0/38 (0) | 0 | 0 | 0 | |||
HSV-1, herpes simplex virus 1; EBV, Epstein-Barr virus; CMV, cytomegalovirus; EV-D68, enterovirus D68; RV-A, rhinovirus A; DENV, dengue virus; JEV, Japanese encephalitis virus; ND, not done.
aCoronavirus set 1 RT-PCR panel was adapted from [12], while coronavirus set 2 was adapted and modified from [13] which can detect broader range of bat coronavirus strains.
Clinical and laboratory characteristics of patients with identified viral infection.
| No. | Viral etiology diagnosis | HIV status | TB history | Outcome | Age, sex | CSF laboratory | CT scan | Clinical characteristics | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell count, cell/μl | Protein, mg/dl | Glucose, mg/dl | CSF/ | High grade fever ≥39°C (days) | Seizure (days) | Headache (days) | Altered consciousness (days) | Skin rash (days) | Myalgia (days) | Focal neurologic signs | GCS | Cognitive impairment | |||||||
| 1 | Confirmed HSV-1 | ⎼ | ⎼ | Low disability | 68, M | 200 | 170 | 62 | 0.4 | Abnormal | + (2) | ⎼ | + (7) | + (2) | ⎼ | ⎼ | ⎼ | 12 | ⎼ |
| 2 | Possible HSV-1 | ⎼ | ⎼ | Death | 21, F | NA | NA | NA | NA | Abnormal | ⎼ | ⎼ | + (9) | + (7) | ⎼ | ⎼ | ⎼ | 3 | + |
| 3 | Possible HSV-1 | ⎼ | ⎼ | Moderate disability | 38, M | NA | NA | NA | NA | NA | + (4) | ⎼ | + (4) | + (1) | ⎼ | + (3) | ⎼ | 8 | ⎼ |
| 4 | Possible HSV-1 | ⎼ | + | Death | 57, F | NA | NA | NA | NA | Normal | + (7) | ⎼ | ⎼ | + (4) | ⎼ | ⎼ | ⎼ | 11 | ⎼ |
| 5 | Possible HSV-1 | ⎼ | ⎼ | Death | 15, F | 0 | 70 | 71 | 0.6 | Abnormal | + (5) | ⎼ | ⎼ | + (2) | ⎼ | ⎼ | + | 9 | ⎼ |
| 6 | Possible HSV-1 | + | + | Death | 37, M | 10 | 240 | 33 | 0.5 | NA | ⎼ | + (1) | + (3) | + (3) | ⎼ | ⎼ | + | 9 | ⎼ |
| 7 | Possible HSV-1 | + | ⎼ | Death | 31, M | NA | NA | NA | NA | NA | ⎼ | ⎼ | + (14) | + (3) | + (30) | ⎼ | + | 14 | + |
| 8 | Possible EBV | + | + | Death | 20, F | NA | NA | NA | NA | Abnormal | + (3) | + (2) | + (14) | + (14) | ⎼ | + (6) | + | 9 | + |
| 9 | Possible EBV | + | + | Moderate disability | 29, M | NA | NA | NA | NA | Normal | + (2) | ⎼ | ⎼ | + (2) | ⎼ | ⎼ | ⎼ | 11 | ⎼ |
| 10 | Confirmed CMV | ⎼ | ⎼ | Death | 15, F | 0 | 38 | 135 | 1.0 | Normal | + (5) | + (7) | ⎼ | + (5) | ⎼ | ⎼ | ⎼ | 10 | ⎼ |
| 11 | Possible EV-D68 | + | ⎼ | Moderate disability | 29, M | NA | NA | NA | NA | Abnormal | ⎼ | + (30) | ⎼ | ⎼ | ⎼ | ⎼ | ⎼ | 15 | ⎼ |
| 12 | Possible RV-A | ⎼ | ⎼ | Moderate disability | 39, F | 0 | 730 | 77 | 0.6 | Normal | ⎼ | + (4) | + (7) | + (1) | ⎼ | ⎼ | ⎼ | 14 | ⎼ |
| 13 | Confirmed DENV | ⎼ | ⎼ | Moderate disability | 16, M | 55 | 20 | 65 | 0.7 | NA | + (5) | + (3) | ⎼ | + (3) | ⎼ | ⎼ | ⎼ | 13 | ⎼ |
| 14 | Probable JEV | ⎼ | ⎼ | Death | 37, F | NA | NA | NA | NA | NA | + (2) | + (2) | ⎼ | + (2) | + (2) | + (20) | ⎼ | 9 | ⎼ |
HSV-1, herpes simplex virus 1; EBV, Epstein-Barr virus; CMV, cytomegalovirus; EV-D68, enterovirus D68; RV-A, rhinovirus A; DENV, dengue virus; JEV, Japanese encephalitis virus; HIV, human immunodeficiency virus; TB, tuberculosis; NA, not available; +, characteristics present; ⎼, characteristics absent.
aBased on Glasgow Outcome Scale: 1 death, 2 persistent vegetative state, 3 severe disability, 4 moderate disability, and 5 low disability
bGlasgow Coma Score: 3–8 severe, 9–12 moderate, 13–15 mild.